Metagenomi ends Moderna collaboration; regains full rights to base editing/RIGS; reports $327.4M cash

Metagenomi Therapeutics, Inc.

Mutually terminated 2021 Strategic Collaboration and License Agreement with Moderna as of April 26, 2024.
Metagenomi regains all development/commercialization rights to its wholly-owned base editing and RIGS programs.
No further payments due from Moderna under the termination agreement; future revenue stream eliminated.
Preliminary unaudited cash and cash equivalents of ~$327.4M as of March 31, 2024.
Company will hold an investor call on May 1, 2024, with updated slide presentation (Exhibit 99.1).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Metagenomi Therapeutics, Inc. terminated Strategic Collaboration and License Agreement with ModernaTX, Inc. (effective 2024-04-26).

Action: termination
Agreement: collaboration
Counterparty: ModernaTX, Inc.
Effective: 2024-04-26

Exact text from the filing

On April 26, 2024 (the “Termination Date”), Metagenomi, Inc. (the “Company”) and ModernaTX, Inc. (“Moderna”) mutually terminated the Strategic Collaboration and License Agreement dated October 29, 2021 (the “Collaboration Agreement”) by and between the Company and Moderna.

View on SEC.gov

292 material agreements filed in the last 30 days. Browse all material agreements →

Metagenomi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-051238

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.